Noventis Biologics

Noventis is a South Korean biotechnology company focused on developing next-generation long-acting biologics for metabolic and rare diseases. The company was founded in 2021 by Dr. Dae-jin Kim, a former lead researcher at Hanmi Pharmaceutical who played a pivotal role in developing the LAPSCOVERY platform. Noventis utilizes its proprietary LAPS-Discovery technology to extend the half-life of proteins and peptides, aiming to reduce dosing frequency and improve patient compliance. Its current pipeline includes candidates for growth hormone deficiency, obesity, and hemophilia, all in the pre-clinical stage of development. The company's approach focuses on optimizing the pharmacokinetic profiles of established therapeutic proteins to create superior bio-betters. Headquartered in Daejeon, Noventis has secured significant venture capital funding to advance its lead programs toward clinical trials.